AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Absci Corporation reported a net loss of $28.71 million for Q3 2025, with a slight improvement in basic loss per share from continuing operations compared to the previous year. This suggests some operational efficiency, but the company's persistent losses and limited revenue remain a challenge. Upcoming clinical trial data and adequate funding are crucial for investors.

Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet